Recurrent Endometrial Cancer

15 clinical trials · Condition

Record	Firm	Date
Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer (NCT05263492)	Virginia Commonwealth University	2022-04-01
Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer (NCT04906382)	Floor Backes, MD	2021-07-01
Pembrolizumab With Axitinib in Recurrent Endometrial Cancer (NCT04197219)	Case Comprehensive Cancer Center	2021-02-01
Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer (NCT03277482)	Dana-Farber Cancer Institute	2018-06-01
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers (NCT03564340)	Regeneron Pharmaceuticals	2018-05-21
Safety and Efficacy of Metronomic Cyclophosphamide, Metformin and Olaparib in Endometrial Cancer Patients (NCT02755844)	Hospices Civils de Lyon	2016-09-23
Pembrolizumab in Ultramutated and Hypermutated Endometrial Cancer (NCT02899793)	Yale University	2016-09-01
Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer (NCT02788708)	Floor Backes	2016-05-27
Study of LY3023414 for the Treatment of Recurrent or Persistent Endometrial Cancer (NCT02549989)	Memorial Sloan Kettering Cancer Center	2015-09-01
Phase I BKM120/Abraxane in Solid Tumors, Expansion Phase Recurrent Endometrial or Ovarian Cancer (NCT02117817)	Rutgers, The State University of New Jersey	2015-02-01
A Phase I Study of Lapatinib (Tykerb) Plus Ixabepilone (Ixempra) as 2nd-line Treatment for Patients With HER-2 Overexpressed Recurrent or Persistent Endometrial Carcinoma or Carcinosarcoma (NCT01454479)	Hung-Hsueh Chou	2011-03-01

Track Recurrent Endometrial Cancer automatically

Every clearance here is in the API, with alerts when new ones post.